Literature DB >> 22568991

The mesenchymal tumor microenvironment: a drug-resistant niche.

Edna Cukierman1, Daniel E Bassi.   

Abstract

Drug and radiation resistance represent a challenge for most anticancer therapies. Diverse experimental approaches have provided evidence that the tumor-associated microenvironment constitutes both a protective shell that impedes drug or radiation access and a permissive or promotive microenvironment that encourages a nurturing cancer (i.e., cancer stem cell) niche where tumor cells overcome treatment- and cancer-induced stresses. Better understanding of the effects of the tumor microenvironment on cancer cells before, during and immediately after chemo- or radiotherapy is imperative to design new therapies aimed at targeting this tumor-protective niche. This review summarizes some of the known mesenchymal stromal effects that account for drug resistance, the main signal transduction pathways associated with this resistance and the therapeutic efforts directed to increase the success of current therapies. Special emphasis is given to environment-mediated drug resistance in general and to cell adhesion-mediated drug resistance in particular.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22568991      PMCID: PMC3427243          DOI: 10.4161/cam.20210

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  160 in total

Review 1.  Ras GTPases: integrins' friends or foes?

Authors:  Kayoko Kinbara; Lawrence E Goldfinger; Malene Hansen; Fan-Li Chou; Mark H Ginsberg
Journal:  Nat Rev Mol Cell Biol       Date:  2003-10       Impact factor: 94.444

Review 2.  Integrins as therapeutic targets: lessons and opportunities.

Authors:  Dermot Cox; Marian Brennan; Niamh Moran
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

Review 3.  Does tumour dormancy offer a therapeutic target?

Authors:  Paul E Goss; Ann F Chambers
Journal:  Nat Rev Cancer       Date:  2010-11-04       Impact factor: 60.716

Review 4.  IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.

Authors:  Markus F Neurath; Susetta Finotto
Journal:  Cytokine Growth Factor Rev       Date:  2011-03-05       Impact factor: 7.638

5.  Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication.

Authors:  K Nakayama; H Nagahama; Y A Minamishima; M Matsumoto; I Nakamichi; K Kitagawa; M Shirane; R Tsunematsu; T Tsukiyama; N Ishida; M Kitagawa; K Nakayama; S Hatakeyama
Journal:  EMBO J       Date:  2000-05-02       Impact factor: 11.598

Review 6.  β1-integrin: a potential therapeutic target in the battle against cancer recurrence.

Authors:  Dalit Barkan; Ann F Chambers
Journal:  Clin Cancer Res       Date:  2011-09-07       Impact factor: 12.531

Review 7.  Framework models of tumor dormancy from patient-derived observations.

Authors:  Christoph A Klein
Journal:  Curr Opin Genet Dev       Date:  2010-12-08       Impact factor: 5.578

8.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

Authors:  B Dankbar; T Padró; R Leo; B Feldmann; M Kropff; R M Mesters; H Serve; W E Berdel; J Kienast
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

9.  CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.

Authors:  Antonella Zucchetto; Dania Benedetti; Claudio Tripodo; Riccardo Bomben; Michele Dal Bo; Daniela Marconi; Fleur Bossi; Debora Lorenzon; Massimo Degan; Francesca Maria Rossi; Davide Rossi; Pietro Bulian; Vito Franco; Giovanni Del Poeta; Silvia Deaglio; Gianluca Gaidano; Francesco Tedesco; Fabio Malavasi; Valter Gattei
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

10.  Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts.

Authors:  Catherine C Park; Hui J Zhang; Evelyn S Yao; Chong J Park; Mina J Bissell
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

View more
  22 in total

1.  Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer.

Authors:  Runbi Ji; Bin Zhang; Xu Zhang; Jianguo Xue; Xiao Yuan; Yongmin Yan; Mei Wang; Wei Zhu; Hui Qian; Wenrong Xu
Journal:  Cell Cycle       Date:  2015-06-19       Impact factor: 4.534

2.  The crucial role of emilin 1 gene expression during progression of tumor growth.

Authors:  Miroslava Rabajdova; Peter Urban; Ivana Spakova; Ladislav Saksun; Rastislav Dudic; Alexander Ostro; Martin Caprnda; Peter Kruzliak; Mariusz Adamek; Maria Marekova
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-31       Impact factor: 4.553

3.  Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.

Authors:  Xiaoli Wang; Sonam Prakash; Min Lu; Joseph Tripodi; Fei Ye; Vesna Najfeld; Yan Li; Myron Schwartz; Rona Weinberg; Paul Roda; Attilio Orazi; Ronald Hoffman
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

4.  The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.

Authors:  Allison S Harney; George S Karagiannis; Jeanine Pignatelli; Bryan D Smith; Ece Kadioglu; Scott C Wise; Molly M Hood; Michael D Kaufman; Cynthia B Leary; Wei-Ping Lu; Gada Al-Ani; Xiaoming Chen; David Entenberg; Maja H Oktay; Yarong Wang; Lawrence Chun; Michele De Palma; Joan G Jones; Daniel L Flynn; John S Condeelis
Journal:  Mol Cancer Ther       Date:  2017-08-24       Impact factor: 6.261

Review 5.  Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets.

Authors:  Yufang Shi; Liming Du; Liangyu Lin; Ying Wang
Journal:  Nat Rev Drug Discov       Date:  2016-11-04       Impact factor: 84.694

Review 6.  Microenvironmental regulation of therapeutic response in cancer.

Authors:  Florian Klemm; Johanna A Joyce
Journal:  Trends Cell Biol       Date:  2014-12-22       Impact factor: 20.808

Review 7.  Miniaturized pre-clinical cancer models as research and diagnostic tools.

Authors:  Maria Håkanson; Edna Cukierman; Mirren Charnley
Journal:  Adv Drug Deliv Rev       Date:  2013-12-01       Impact factor: 15.470

8.  Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.

Authors:  Sunitha Kakarla; Kevin K H Chow; Melinda Mata; Donald R Shaffer; Xiao-Tong Song; Meng-Fen Wu; Hao Liu; Lisa L Wang; David R Rowley; Klaus Pfizenmaier; Stephen Gottschalk
Journal:  Mol Ther       Date:  2013-06-04       Impact factor: 11.454

9.  Tumor microenvironment indoctrination: an emerging hallmark of cancer.

Authors:  Jacky G Goetz
Journal:  Cell Adh Migr       Date:  2012-05-01       Impact factor: 3.405

10.  The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells.

Authors:  Felix Nwajei; Marina Konopleva
Journal:  Adv Hematol       Date:  2013-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.